Recent Updates
Recently added Catalysts
DFTX Positive Sentiment

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Definium Therapeutics announced its participation in upcoming investor conferences, including the Stifel 2026 Healthcare Conference. The management team will engage with investors to discuss the company's innovative therapeutics targeting psychiatric and neurological disorders. This involvement aims to strengthen relationships with potential investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Definium is participating in key investor conferences.
  • Management team engagement may enhance investor relations.
  • Focus on psychiatric and neurological disorders is promising.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+130%
120-day peak, hindsight
Typical move
15.7%
average across 4 past catalysts
Cash runway
~59 mo
Low dilution risk
Lead asset
DT120
Phase 3 · Major Depressive Disorder

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc

Frequently Asked Questions

What conferences will Definium participate in?

Definium will participate in the Stifel 2026 Healthcare Conference.

When is the Stifel 2026 Healthcare Conference?

The conference is scheduled for November 10, 2026, at 9:20 AM ET.

What is Definium Therapeutics focused on?

Definium focuses on therapeutics for psychiatric and neurological disorders.

Who will represent Definium at the conferences?

Members of Definium's management team will represent the company.

ShareAdd on Google
Tags: DFTX Definium Therapeutics investor conferences psychiatric disorders neurological disorders
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$1084M liquidity · $18M/mo burn
~59 mo
Low dilution risk
Lead asset
DT120Phase 3
Major Depressive Disorder →

Catalyst track record

+130%
best trade around DFTX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for DFTX.

See every catalyst's timing & PoA →